**Lymphoma**

- **Lymphoma (Hodgkin or Non-Hodgkin)**
  - **Lymphoma, not otherwise stated**
  - **Diffuse Large B Cell Lymphoma and Hodgkin Lymphoma**
  - **Various Non-Hodgkin lymphomas**
    - **Mycosis fungoides (MF) and Sézary syndrome (SS)**
    - **T-cell lymphomas**
    - **Diffuse large B-cell lymphoma**
    - **Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)**

**Limited trial; not open ETCTN-wide; Version Date: December 8, 2022**

**10014:** A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies

**10037:** A phase I study with an expansion cohort of duvelisib and nivolumab in mycosis fungoides (MF) and Sézary syndrome (SS)

**10050:** Phase 1/2 Study of the Combination of Oral DNMT Inhibition and Checkpoint Inhibition in Relapsed DLBCL and HL

**10059:** A Phase 2 Study of Mosunetuzumab or Rituximab in Nodular Lymphocyte-Predominant Hodgkin Lymphoma

**10060:** A Phase 1 Study of Mosunetuzumab with Polatuzumab Vedotin and Lenalidomide (M+Pola+Len) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

**10335:** A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)

**10347:** A phase I study with an expansion cohort of duvelisib and nivolumab in mycosis fungoides (MF) and Sézary syndrome (SS)

**10384:** A Phase 1b/2 Study of Hu5F9-G4 (Magrolimab) in Combination with Mogamulizumab in Relapsed/Refractory Treated T-Cell Lymphoma

**10449:** Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas

**10499:** A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)

**10500:** Phase 1/Expansion study of tazemetostat plus belinostat for the treatment of relapsed or refractory lymphoma

**10508:** A Phase 1/2 Study of the Combination of Oral DNMT Inhibition and Checkpoint Inhibition in Relapsed DLBCL and HL

**10590:** A Phase 2 Study of Mosunetuzumab or Rituximab in Nodular Lymphocyte-Predominant Hodgkin Lymphoma

**NOTE:** * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: December 8, 2022